Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein

Journal of Clinical Oncology

Volumn 30, Issue 3, 2012, Pages 340-341

  Chen, Nianhang ^a   Kasserra, Claudia ^a   Kumar, Gondi ^a   Palmisano, Maria ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; LENALIDOMIDE; RAPAMYCIN; TEMSIROLIMUS;

AREA UNDER THE CURVE; CANCER PATIENT; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN;

EID: 84856020250     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.4163     Document Type: Letter

References (15)

1. Hofmeister CC, Yang X, Pichiorri F, et al: Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 29:3427-3434, 2011
2. Kumar GN, Surapaneni S, Lau H, et al: Interaction of lenalidomide with human drug transporters in vitro. Presented at the 15th North American Regional International Society for the Study of Xenobiotics Meeting, San Diego, CA, October 12-16, 2008 (abstr 382)
3. Celgene: REVLIMID (lenalidomide) prescribing information. http://www .revlimid.com/pdf/REVLIMID-PI.pdf
4. International Transporter Consortium, Giacomini KM, Huang SM, et al: Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236, 2010
5. Chen N, Wen L, Lau H, et al: Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol [epub ahead of print on October 29, 2011]
6. Chen N, Lau H, Kong L, et al: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475, 2007 (Pubitemid 350115306)
7. Fenner KS, Troutman MD, Kempshall S, et al: Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181, 2009
8. Wyeth Pharmaceuticals: TORISEL Kit (temsirolimus) prescribing information. http://labeling.pfizer.com/showlabeling.aspx?ID=490
9. Buckner JC, Forouzesh B, Erlichman C, et al: Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs 28:334-342, 2010
10. Wyeth Pharmaceuticals: RAPAMUNE (sirolimus) prescribing information. http://labeling.pfizer.com/showlabeling.aspx?id=139
11. Wacher VJ, Silverman JA, Wong S, et al: Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther 303:308-313, 2002
12. Zimmerman JJ: Exposure-response relationship and drug interactions of sirolimus. AAPS J 6, 2004 (article 28)
13. Kumar G, Lau H, Laskin O: Lenalidomide: In vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol 63:1171-1175, 2009
14. Bridoux F, Arnulf B, Moreau S: Pharmacokinetics, efficacy and safety of lenalidomide [LEN] in myeloma patients with renal impairment: Results from the prospective study "REVIR." Blood 118, 2011 (abstr 2934)
15. Iida S, Chou T, Okamoto S, et al: Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol 92:118-126, 2010